A Phase 1b, Multi-Center, Open Label, Uncontrolled, Serial Cohort, Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Daily Oral Doses of ZSTK474 in Subjects With Advanced Solid Malignancies.
Phase of Trial: Phase I
Latest Information Update: 24 Jan 2014
At a glance
- Drugs ZSTK 474 (Primary)
- Indications Anal cancer; Cholangiocarcinoma; Colorectal cancer; Gynaecological cancer; Non-small cell lung cancer; Pancreatic cancer; Soft tissue sarcoma; Solid tumours
- Focus Adverse reactions
- Sponsors Zenyaku Kogyo
- 24 Jan 2014 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
- 23 Oct 2013 Results presented at the 25th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.
- 04 Sep 2013 Planned end date changed from 1 Sep 2013 to 1 Dec 2013 as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History